Capricor Therapeutics, Inc. (CAPR)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
6.88 USD
-0.59
(-7.898%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 6.85 -0.03 (-0.030%) ⇩ (Oct. 13, 2026, 7:54 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 4:52 a.m. EDT
The long-term investment case is severely compromised by a decade-long structural decline; the stock has lost nearly 80% of its value over the last nine years, with the most recent annual performance showing another significant drop. Despite the company's potential in gene therapy, the market has consistently punished the business, and the balance sheet reflects ongoing losses with negative free cash flow. While the short-term outlook sees a spark of interest due to upcoming legal and regulatory milestones, the trading activity is purely speculative, driven by bets on a binary event rather than sustainable growth. The statistical forecast models also lean negative, reinforcing the view that the recent price action is noise rather than a reversal. Without a proven track record of profitability or sustained revenue growth, this remains a high-risk speculative vehicle rather than a viable investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.885378 |
| AutoETS | 1.022895 |
| AutoARIMA | 1.022899 |
| MSTL | 1.024234 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 0.18 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.196 |
| Excess Kurtosis | -0.89 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 36.977 |
| Market Cap | 399,996,256 |
| Forward P/E | -4.74 |
| Beta | 0.61 |
| Website | https://www.capricor.com |
As of Oct. 10, 2026, 4:52 a.m. EDT: Speculators are positioning aggressively for volatility rather than a specific directional outcome. Call volume is heavily skewed toward out-of-the-money strikes (10, 15, 28, 33, 50), indicating a speculative bet on a massive biotech-style spike. However, put volume is equally intense, particularly at deep strikes (3, 7, 8) and far OTM levels (28, 33, 50), creating a 'straddle' environment where traders are betting on a binary event (FDA decision/legal ruling) causing a gap up or a catastrophic drop. The implied volatility surface shows massive spikes at extreme strikes, confirming this is a volatility play, not a trend-following setup.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.11659193 |
| Address1 | 10,865 Road to the Cure |
| Address2 | Suite 150 |
| All Time High | 3,500.0 |
| All Time Low | 0.88 |
| Ask | 8.94 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 2.3 - Buy |
| Average Daily Volume10 Day | 4,820,500 |
| Average Daily Volume3 Month | 6,973,103 |
| Average Volume | 6,973,103 |
| Average Volume10Days | 4,820,500 |
| Beta | 0.606 |
| Bid | 5.23 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 4.237 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.88 |
| Current Ratio | 7.346 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 7.3999 |
| Day Low | 6.87 |
| Debt To Equity | 36.977 |
| Display Name | Capricor Therapeutics |
| Dividend Date | 1,559,692,800 |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,653,000 |
| Earnings Call Timestamp Start | 1,786,653,000 |
| Earnings Timestamp | 1,786,651,200 |
| Earnings Timestamp End | 1,794,340,800 |
| Earnings Timestamp Start | 1,794,340,800 |
| Ebitda | -133,066,296 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.902 |
| Enterprise Value | 253,106,832 |
| Eps Current Year | -1.45222 |
| Eps Forward | -1.45111 |
| Eps Trailing Twelve Months | -2.45 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.7166 |
| Fifty Day Average Change | -0.8365998 |
| Fifty Day Average Change Percent | -0.1084156 |
| Fifty Two Week Change Percent | 11.659193 |
| Fifty Two Week High | 40.37 |
| Fifty Two Week High Change | -33.489998 |
| Fifty Two Week High Change Percent | -0.8295764 |
| Fifty Two Week Low | 2.96 |
| Fifty Two Week Low Change | 3.92 |
| Fifty Two Week Low Change Percent | 1.3243244 |
| Fifty Two Week Range | 2.96 - 40.37 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,171,377,000,000 |
| Float Shares | 42,602,507 |
| Forward Eps | -1.45111 |
| Forward P E | -4.741198 |
| Free Cashflow | -89,191,328 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 231 |
| Fullday Change | -0.6199999 |
| Fullday Change Percent | -8.299865 |
| Fullday Price | 6.88 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -99,734,976 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.09437 |
| Held Percent Institutions | 0.76294 |
| Implied Shares Outstanding | 58,138,989 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.nilethera.com/investor.html |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,559,692,800 |
| Last Split Factor | 1:10 |
| Long Business Summary | Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California. |
| Long Name | Capricor Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 399,996,256 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_29535381 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -129,416,560 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 543,018,157 |
| Number Of Analyst Opinions | 5 |
| Open | 7.32 |
| Operating Cashflow | -103,995,608 |
| Operating Margins | 0.0 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.38 |
| Phone | 858 727 1755 |
| Post Market Change | -0.03000021 |
| Post Market Change Percent | -0.43604955 |
| Post Market Price | 6.85 |
| Post Market Time | 1,791,935,679 |
| Previous Close | 7.47 |
| Price Eps Current Year | -4.7375746 |
| Price Hint | 2 |
| Price To Book | 1.6237905 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.219 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.3 |
| Region | US |
| Regular Market Change | -0.59 |
| Regular Market Change Percent | -7.89826 |
| Regular Market Day High | 7.3999 |
| Regular Market Day Low | 6.87 |
| Regular Market Day Range | 6.87 - 7.3999 |
| Regular Market Open | 7.32 |
| Regular Market Previous Close | 7.47 |
| Regular Market Price | 6.88 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 2,632,417 |
| Return On Assets | -0.33635 |
| Return On Equity | -0.737 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 58,138,989 |
| Shares Percent Shares Out | 0.3238 |
| Shares Short | 18,825,352 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 22,183,275 |
| Short Name | Capricor Therapeutics, Inc. |
| Short Percent Of Float | 0.3575 |
| Short Ratio | 4.84 |
| Source Interval | 15 |
| State | CA |
| Symbol | CAPR |
| Target High Price | 54.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 27.0 |
| Target Median Price | 25.0 |
| Total Cash | 237,934,784 |
| Total Cash Per Share | 4.093 |
| Total Debt | 91,045,360 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.45 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 22.10755 |
| Two Hundred Day Average Change | -15.22755 |
| Two Hundred Day Average Change Percent | -0.6887941 |
| Type Disp | Equity |
| Volume | 2,632,417 |
| Website | https://www.capricor.com |
| Zip | 92,121 |